Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Erbitux probe

Executive Summary

Hearings stemming from the House Energy & Commerce investigation of ImClone and its BLA for Erbitux are not likely to happen this year, Health Subcommittee Chairman Michael Bilirakis (R-Fl.) told reporters April 16. Committee Chairman Billy Tauzin (R-La.) added: "Staff has been meeting with FDA and stakeholders, but there has been no decision made as of yet." The House investigation is focusing on ImClone's representations to shareholders regarding the oncologic product and may include FDA review policies (1"The Pink Sheet" March 25, p. 20)...

You may also be interested in...



FDA Refuse-To-File Policy Records Requested Under House ImClone Probe

The House Commerce/Oversight Subcommittee is asking FDA to provide records relating to its policy on refuse-to-file letters, as part of its broadening investigation into ImClone

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

UsernamePublicRestriction

Register

PS039708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel